Abbott Labs
ABT Large CapHealthcare · Medical Devices
Updated: May 20, 2026, 22:09 UTC
Key Metrics
Valuation Analysis
About the Company
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides
Abbott Labs Stock at a Glance
Abbott Labs (ABT) is currently trading at $88.37 with a market capitalization of $153.9B. The trailing P/E ratio stands at 24.75x, with a forward P/E of 14.57x. The 52-week range spans from $81.97 to $139.06; the current price is 36.5% below the yearly high. Year-over-year revenue growth stands at +7.8%. The net profit margin stands at 13.9%.
💰 Dividend
Abbott Labs pays an annual dividend of $2.52 per share, representing a yield of 2.85%. The payout ratio stands at 67.23%.
📊 Analyst Rating
25 analysts rate Abbott Labs (ABT) on consensus: Buy. The average price target is $118.64, implying +34.25% from the current price. Analyst price targets range from $92.00 to $143.00.
Investment Thesis: Strengths & Weaknesses
- High gross margin of 56.5% — indicates pricing power
- Analyst consensus: Buy
- Solid dividend yield of 2.85%
- Positive free cash flow
No significant red flags in current metrics.
Technical Snapshot
Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).
Risk Profile
The data points to relatively defensive market behavior.
Trading Data
💵 Dividend Info
Related Stocks in the Same Sector
Abbott Labs 2026: Libre FreeStyle growth vs. PFAS lawsuits — the dividend aristocrat under stress
The Real Story
Abbott Laboratories in 2026 is a healthcare conglomerate with four segments (Established Pharma, Diagnostics, Nutritional, Medical Devices) — and an extremely skewed value distribution. FreeStyle Libre, the continuous glucose monitoring (CGM) system, generates 18% of group revenue but an estimated 40% of EBIT. Q4 2025: Libre revenue $1.9B (+22% YoY), 7.2M active users worldwide, market share in the non-insulin type-2 segment ~60%.
But the stock sits at $84.89 — 39% below the 52-week high ($139.06) and only 3.5% above the 52-week low ($81.97). What happened? Three themes weigh: (1) competition from Dexcom G7 and the newer Stelo direct-to-consumer line; (2) GLP-1 drugs (Ozempic, Mounjaro) reduce the long-term type-2 diabetic population; (3) a wave of PFAS lawsuits (forever chemicals in medical sensors) is building.
Operationally Abbott runs stable: Q4 2025 revenue $45.1B (+7.8% YoY), operating margin 13.5%, FCF $6.3B, gross margin 56.5% — better than big-pharma average (Pfizer, BMS, Merck below 50%). Dividend raised for 53 straight years — one of the Dividend Kings.
The central 2026 question: is Abbott a hidden value opportunity at forward P/E 14, or has the market recognized that Libre growth is structurally decelerating with no re-acceleration in sight?
What Smart Money Thinks
Abbott is a stability anchor in 13F filings, not a smart-money hotspot. The Bill & Melinda Gates Foundation Trust holds 17.8M shares (~$1.5B) — historically one of its largest non-index positions and an indicator for the long-term-health theme. Capital Group holds 38M shares as a top holding across several actively managed funds.
Institutional ownership 79%. Vanguard 9.3%, BlackRock 7.8%, State Street 4.2%, T. Rowe Price 3.1%. Hedge fund activity Q4 2025: Glenview Capital (Larry Robbins) built a new position at $88-92 ($340M), clearly long the Libre re-acceleration plus spin-off optionality thesis.
Insiders 2025: CEO Robert Ford sold $14.2M (10b5-1 plan), CFO Phil Boudreau sold $4.1M — standard compensation-vesting sales. Two insider purchases in 2025: Director Reuben Mark bought $580k at $85, Director Roxanne Austin bought $720k at $84 — both near the 52-week lows, a slightly bullish aggregate signal.
Explore the BMI Smart-Money Tracker →
📈 The 3 Real Bull Points
Despite the competition concerns, Libre keeps growing +22% YoY to $7.4B annually. The global CGM market sits at $11B (2025) and is expected to grow to $30-35B by 2030 — Abbott and Dexcom share ~85% of it today, with Abbott at 53% market share. With only 20% diabetes penetration (vs. 60% achievable long-term), this is a 15-year growth story.
Strategic accelerators 2026-2027: Libre Rio (over-the-counter version for type-2 non-insulin users, FDA approval May 2024), Lingo (lifestyle/sport CGM, launched 2024), ketone sensor in the FDA pipeline for 2026/27. At full scale the OTC market alone adds a $5-8B TAM.
Abbott is not Pfizer (pharma concentration) or Stryker (pure med-tech). Four pillars: Medical Devices (45% of revenue), Established Pharma (24%), Diagnostics (19%), Nutritional Products (12%). If Libre growth dips, structural heart business (MitraClip, Navitor TAVR), diabetes care devices, nutrition (Ensure, Glucerna, Similac) and diagnostics compensate.
Beta 0.65 — one of the most defensive healthcare mega-caps. In the last three bear markets (2018, 2020-COVID, 2022) ABT averaged a -14% drawdown vs. S&P -23%. For an allocation that needs stability through sector rotations, Abbott remains a top candidate.
Current dividend yield 2.97% ($2.52 per share annualized), 53 years of uninterrupted increases, 10-year dividend CAGR 7.8%. At forward P/E 14, ABT trades historically cheap — 5-year median 19.5, 10-year median 21. The dividend-king premium spread is at an 8-year low.
FCF yield: $6.3B FCF / $148B market cap = 4.3%, plus 0.5% buyback yield. Total shareholder yield ~8% on a low-beta dividend king. Even at 0% growth that would be an 8% total return — at the current 6-8% earnings growth path it leans toward 11-13%.
📉 The 3 Real Bear Points
Since 2024 lawsuits have been growing against Abbott and other med-tech providers over per- and polyfluoroalkyl substances (PFAS) in stent coatings, sensor membranes and some infusion components. The 2024 EPA classification as hazardous substances triggered a wave of personal injury suits, with the centralized MDL pending in the Eastern District of South Carolina (Judge Gergel).
Worst-case estimates: $1.5-4B over 5-7 years (compared to 3M's $10.3B PFAS settlement in 2023; Abbott has materially less PFAS exposure). Material damage? At $6.3B FCF annually: yes, but absorbable. Price-relevant? Yes — uncertainty alone compresses the multiple until settlement clarity arrives in 2027.
Ozempic, Wegovy, Mounjaro and Zepbound lower HbA1c in type-2 diabetics so significantly that many patients no longer actively need a CGM or can de-escalate therapy. JP Morgan study 2024: 12% of Libre users started GLP-1 treatment within 18 months, and 28% of those reduced CGM use.
If GLP-1 penetration rises to 40-50% of the type-2 population (Lilly forecast for 2030), the addressable Libre market shrinks by an estimated 20-30% long term. Abbott counters with Lingo (non-diabetes lifestyle CGM) and OTC market opening, but margins there are lower and competition is denser (Apple, Garmin, Oura want in).
Earnings growth of -19.7% over the last 12 months is a warning signal. Background: loss of the COVID-test special-revenue base (2023 still $1.9B revenue, 2025 only $200M), plus FX headwinds from a strong dollar. Operating margin 13.5% vs. 5-year average 15.8% — 230 bps margin compression.
If margin compression is structural (input-cost inflation in med-device components, China supply chain shifts, higher R&D for pipeline replenishment), the 2026 earnings recovery could be weaker than the 14 forward P/E implies. A bear-case 2026 EPS of $4.80 vs. consensus $5.15 would push forward P/E to 17.7 — the stock would no longer be cheap.
Valuation in Context
Abbott at $84.89 trades at TTM P/E 23.8 (distorted by earnings drop) and forward P/E 14.0 (clean number). EV/EBITDA 14.8 slightly above 10-year median 13.4. P/S 3.28 slightly below median 3.4. PEG 1.25 — fair for healthcare quality.
Three models: (1) DDM (dividend discount) with 7.5% dividend CAGR and 8.5% required return → fair value $98-105. (2) Sum-of-the-parts: Med Devices ($85B, EV/Sales 4.2x), Established Pharma ($28B, 2.6x), Diagnostics ($24B, 2.9x), Nutritional ($16B, 2.3x) - net debt $4B = $149B = ~$85/share. (3) Peer multiple: J&J forward P/E 15, Medtronic 16, Stryker 28 — Abbott plausibly between J&J and Medtronic at forward P/E 16-18 → $82-92.
Average ~$90-100. Current price $84.89. Upside to midpoint: +6% to +18%. Plus 3% dividend yield gives an expected 1-year total return of ~9-20%. Main model risk: PFAS settlement outcome — worst-case DCF with $3B cumulative liability brings fair value to $75.
🗓️ Next 3 Catalyst Dates
- July 16, 2026: Q2 2026 earnings — Libre Rio US ramp-up update (first OTC quarterly data), consensus $5.2B medical-device revenue, +9% YoY
- September 2026: FDA PDUFA date for Libre 4 — next-generation sensor with multi-analyte capability (glucose + ketone + lactate); sentiment lever on approval
- Q1 2027: First hearing in the PFAS MDL before Judge Gergel — overview of case count, possibly bellwether trial selection. Main valuation catalyst for the next 18 months.
💬 Daniel's Take
Abbott has been in my personal portfolio for 5 years — small position (~3% portfolio), but stable. The story fits: dividend king, low volatility, defensive healthcare, Libre as growth engine. At $85, the valuation is for the first time since 2020 actually attractive — forward P/E 14 is well below the 10-year median 21.
What keeps me from a full position: the PFAS liability cloud. It will take at least 12-18 months until there is clarity. In the meantime, further negative headlines could push the stock to $75-80. The long-term thesis is intact, but the timing is unclear.
My 2026 setup: add at $80 to 5% portfolio weight, scale to 7% at $75 (-12% from here). On PFAS clarity (positive or neutral), ABT could trend back to $100-110 — that would be +20-30% plus dividend. This is not investment advice — dividend kings are rarely dramatic, but they are not risk-free during liability clouds either.
Sources (3)
Disclaimer: This article is not investment advice. Investing in stocks carries risks, including total loss.
Where can I buy Abbott Labs?
Compare top-rated brokers — low fees, trusted providers, fully regulated.